Online inquiry

IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10619MR)

This product GTTS-WQ10619MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Dementia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10619MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7335MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ12462MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ1505MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ12467MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ4996MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ1354MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ5703MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ8418MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW